The twice daily type 2 diabetes drug Jentadueto has been made available in tablet form on prescription in the United States following approval by the Food and Drug Administration (FDA).
The medicine, taken by diabetes patients to help manage their blood sugar levels, is produced by pharma giants Eli Lilly and Boehringer Ingelheim. It combines two separate diabetes drugs, the dipeptidyl peptidase-4 (DPP-4) inhibitor, linaglipti, and metformin, into a single tablet. Linagliptin is already sold independently in the US as Tradjenta 5mg once-daily tablets.
The prescription medicine is recommended to be taken with both diet and exercise to improve glycaemic control in adults suffering from type 2 diabetes when a treatment with both linagliptin and metformin is considered suitable.
The prescription drug should not be taken by people with either type 1 diabetes or diabetic ketoacidosis, and has a warning on its label about the potential risk of lactic acidosis, a complication from metformin accumulation during treatment.
Jentadueto offers doctors the ability to adjust the amount of metformin prescribed according to its effectiveness and tolerability, and is available in three dosage strengths, 2.5 mg linagliptin/500 mg metformin hydrochloride, 2.5 mg linagliptin/850 mg metformin hydrochloride and 2.5 mg linagliptin/1000 mg metformin hydrochloride.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…